Poll: In an RCC patient with a 4- to 7-cm tumor and no metastasis, which one of the following treatments would you recommend?

Initial results on ADI-270 are anticipated for the first half of 2025.

Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.

“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.

The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.

"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.

According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”